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life criteria or even QoL impact on family. ConClusions: This analysis presented 
a possible scenario for the implementation of VBA. None of the drugs with a nega-
tive recommendation would get a positive recommendation under this scenario. 
The products at most risk are those currently accepted using end-of-life criteria. 
However, how the new value elements will be weighted has yet to be determined.
PHP195
THe evoluTion of inTernaTional reference Pricing: an analysis of  
39 counTries
Lockwood C., Marinoni G., Ando G.
IHS, London, UK
objeCtives: To characterise country-level changes to international reference 
pricing (IRP) policy frameworks across 39 markets, and understand how coun-
tries amend this tool. Methods: Qualitative interviews were conducted with 50 
stakeholders across 39 markets, representing 37 payers or payer influencers and 13 
industry stakeholders. These interviews focused on country-level IRP methodology, 
both past and present. Extensive secondary research of government websites and 
existing literature was also conducted. A qualitative and semi-quantitative analysis 
of these findings was undertaken to identify key trends in how IRP has been modi-
fied as a policy tool since implementation. Results: Of the markets considered, 
IRP has remained comparatively stable – in terms of both the countries comprising 
the reference basket and the underlying formula for determining the reference price 
remaining unchanged – in just under one-third of the 39 markets. In contrast, just 
over one-third of these markets have modified their IRP baskets to include one or 
more additional countries with the objective of lowering prices. A smaller number 
have made substantive changes to the IRP formula itself, notably with four markets 
transitioning from taking the average price of their basket as a reference to either 
taking the average of the three lowest or taking the lowest. ConClusions: IRP 
serves as a dynamic policy tool, changing to reflect individual country circum-
stances and broader policy reform over time. While a number of markets have 
maintained a stable IRP regime since inception, a larger number have made some 
changes, the most common being to add one or more markets to the reference 
basket. Although changes to IRP are mostly concentrated in Eastern European mar-
kets, as well as Western European markets most impacted by the recent economic 
crisis, the present study also suggests that there is considerable variation across 
geographies and time in how countries adapt their use of IRP.
PHP196
Making sense of nice’s ‘new’ MTa and sTa Process guide: a narraTive 
synTHesis
Urbich M., Mildred M.
Boehringer Ingelheim Ltd, Bracknell, UK
objeCtives: NICE’s guides to the process of Multiple Technology Appraisals (MTA) 
and Single Technology Appraisals (STA) provide a valuable source of information 
to enable stakeholders to engage in Health Technology Appraisals (HTAs). NICE 
recently conducted a review of the process guides which has implications for all 
stakeholders involved with MTAs and STAs. The objective of this analysis was to 
identify the number and type of amendments within the guides in order to high-
light the most important changes for consultees and commentators. Methods: 
Narrative synthesis was used to systematically identify, classify and explore the 
impact of the proposed amendments to the MTA and STA process guides. The 
hypothesis was that the amalgamation of the MTA and STA guides would simplify 
both TA processes whilst increasing rigour and transparency. Sources of reference 
were the draft of the new process guide, the NICE Senior Management Team Board 
Cover Paper, and the 2009 MTA and STA process guides. Results: Amendments 
were classified as relating to the process itself (26%), data and confidential infor-
mation (44%), terminology (7%), and others (22%). Of the 27 amendments to the 
MTA and STA process guides, 4 (15%) were identified as major amendments which 
warrant specific appreciation. Major amendments included: (1) the STA decision 
problem meeting moving to after the Department of Health referral; (2) stricter rules 
around the marking of confidential information; (3) full publication of MTAs; and 
(4) MTAs now have the opportunity to go straight to Final Appraisal Determination 
(FAD) following the first committee meeting. ConClusions: The draft process 
guide suggests that the new MTA and STA processes will foster greater engage-
ment between stakeholders early on, increase transparency, and enable patients 
to have quicker access to innovative medicines which are able to go straight to FAD.
PHP197
MeTHodological requireMenTs regarding qualiTy of life 
MeasureMenT in THe early assessMenT of BenefiT in gerMany
Blome C., Augustin M., Lohrberg D.
University Medical Center Hamburg-Eppendorf, Hamburg, Germany
objeCtives: In Germany, an early assessment of benefit (EAB) is required for new 
medicines since January 2011. The pharmaceutical manufacturer submits a dossier 
on additional benefit over comparative treatment which is subsequently evaluated 
by the Institute for Quality and Efficiency in Health Care (IQWiG). Stakeholders can 
comment on the evaluation in a formal comments procedure. The final decision 
on additional benefit is made by the Federal Joint Committee (G-BA); it provides the 
basis for price negotiations between manufacturer and statutory health insurance 
funds. Quality of life (QoL) is one of four criteria for benefit evaluation. This qualita-
tive study aimed to determine methodological requirements for QoL measurement 
in the German EAB. Methods: A qualitative content analysis according to Mayring 
was conducted. Documents of all EABs completed until December 2013 (including 
dossier, IQWiG evaluation, protocol of the oral hearing, and G-BA decision) were 
searched for the term QoL or synonyms. Relevant passages were extracted and 
reduced to key content by two researchers independently. On the basis of subse-
quent consensus building, recurring themes of the term’s usage in the EAB process 
were identified. Results: In the 66 early assessments of benefit included in the 
analysis, a range of methodological requirements regarding QoL assessment, analy-
sis, and interpretation emerged. Dominant topics included: the appropriate level of 
disease-specificity of QoL instruments; required evidence on an instrument’s valid-
ity and on the validity of a minimal important difference; appropriate duration of 
QoL assessment; consequences of potential bias due to unblinded study design or 
missing data; interpretation of results that differed between subscales of an instru-
ment; non-acceptance of surrogate endpoints for QoL. ConClusions: Evidence 
on QoL can have high impact on the additional benefit determined by the G-BA. 
Therefore, QoL assessment and analysis in clinical studies that shall enter benefit 
dossiers should confirm with a range of methodological requirements.
PHP198
exPloring THe flaws in cosT-effecTiveness Models THaT lead To 
rejecTion of nice suBMissions
Griffiths E.A., Hendrich J.
PAREXEL, London, UK
objeCtives: New health technologies are required to demonstrate both clinical and 
cost-effectiveness before recommendation by the National Institute for Health and 
Care Excellence (NICE) for reimbursement in England; however, a large proportion 
of submissions are rejected due to non-robust economic analysis. Published NICE 
guidance includes a comprehensive critique of submitted economic evidence so, to 
help inform future submissions, we assessed the flaws in cost-effectiveness models 
leading to rejection by NICE. Methods: All NICE single technology appraisals from 
January 2006 to May 2014 were included in the analysis. Multiple technology apprais-
als, resubmissions, vaccination programmes, requests for advice, and submissions 
where an incremental cost-effectiveness ratio (ICER) could not be determined were 
excluded. Recommendations and reasoning across decisions were extracted, with 
a focus on the critique of the economic evidence. Results: 121 NICE submissions 
met the inclusion criteria, 28 (19.8%) of which were rejected. Non-robust economic 
analysis was one of the listed reasons for rejection in 75.0% (21) of cases, and in all 
cases where the submitted ICER was below the £30,000 cost-effectiveness thresh-
old. Within these submissions, the key drivers behind rejection due to non-robust 
cost-effectiveness modelling were: a high level of uncertainty in inputs (leading to a 
sensitive or unreliable ICER) (in 90.5% of cases); mishandling of data (e.g., overstated 
treatment effect or failure to account for adverse events) (85.7%); misalignment to 
the reference case (e.g., inappropriate comparator or weak methodology) (38.1%); 
and unrealistic assumptions (38.1%). ConClusions: Non-robust economic analysis 
is one of the main reasons behind rejection of NICE submissions, largely due to high 
uncertainty, or selective use of data to favor the health technology being appraised. 
Early modelling may allow manufacturers to identify and address sources of uncer-
tainty or weakness early in the clinical development process, in order to construct 
a convincing and robust economic argument ahead of reimbursement submission.
PHP199
is iT PossiBle To PredicT THe MarkeT access of a new PHarMaceuTical 
in gerMany? a sysTeMaTic evaluaTion of federal joinT coMMiTTee 
decisions on early BenefiT assessMenTs according To THe gerMan 
law for reforMing THe MarkeT of PHarMaceuTicals
Schwander B.1, Banz K.2, Kaier K.3, Walzer S.4
1AHEAD GmbH, Loerrach, Germany, 2Outcomes International, Basel, Switzerland, 3University 
of Freiburg, Freiburg, Germany, 4MArS Market Access & Pricing Strategy GmbH, Weil am Rhein, 
Germany
objeCtives: As of 1st January 2011 the German drug market is regulated by the 
act of the reorganization of the pharmaceutical market (AMNOG). Since then the 
normal procedure for reimbursement of a new pharmaceutical is an early benefit 
assessment by the joint federal committee (G-BA) which determines one of six 
additional benefit levels. According to AMNOG any specification of the reimburse-
ment price shall be based on the outcomes of the early benefit assessment. Hence 
this assessment takes a key role for market access of a new drug in Germany which 
poses the question whether it is possible to predict the level of additional benefit 
that will be established by the G-BA. Methods: In order to evaluate a possible 
predictor of G-BA decisions, the ‘evaluation of pharmaceutical innovations (EVITA)’ 
score was calculated and retrospectively compared with 40 published G-BA deci-
sions. The EVITA algorithm evaluates a new compound for a given indication and in 
relation to a relevant comparator on the basis of randomized controlled trial (RCT) 
evidence. EVITA translates the RCT outcomes on the therapeutic benefit and risk 
profile into rating points, which are expressed as a total EVITA score. Results: 
Univariate ordinary least squares and ordered logit regression analyses show sta-
tistically significant correlations between EVITA scores and the G-BA additional 
benefit levels. Moreover, for the prediction of an additional benefit level of at least 
‘minor’, an EVITA score cutpoint of ≥ 3 is associated with a sensitivity of 100% and 
a specificity of 80%. For the prediction of an additional benefit level of at least ‘con-
siderable’, an EVITA score cutpoint of ≥ 7.5 is associated with a sensitivity of 100% 
and a specificity of 93.1%. ConClusions:  The present investigation indicates that 
the EVITA score may have the potential for the prediction of G-BA decisions related 
to AMNOG early benefit assessments.
PHP200
selecTion of ToPics for nice TecHnology aPPraisal 2005-2011: wHaT 
MaTTers MosT?
Ward D.J.1, Shiyka A.2, Fellows R.1
1NIHR Horizon Scanning Centre, Birmingham, UK, 2University of Birmingham, Birmingham, UK
objeCtives: The National Institute for Health and Care Excellence (NICE) under-
takes appraisals of selected health technologies, and those judged to be cost-
effective must be funded for use on the National Health Service in England and 
Wales. Obtaining a positive appraisal decision is therefore important to commer-
cial developers seeking market access, who require consistent application of topic 
selection criteria (which were amended in 2009). We sought to establish which 
characteristics of drugs or their indications were most important in the decision 
to undertake an appraisal. Methods: All marketing authorisations (MAs) granted 
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2005-2011 for new drugs and new indications for existing drugs were identified 
from the European Medicines Agency (EMA) website. The decision to undertake an 
appraisal was obtained from the NICE website and NIHR Horizon Scanning Centre 
records, and the associations between this and characteristics of the drug and 
intended patient population were then determined. Results: For 2005-2011, we 
identified 134 MAs granted by the EMA (116 new drugs and 18 new indications) of 
which 72 (54%) were selected for appraisal. The decision to undertake an appraisal 
was significantly associated with an MA granted 2009-2011 (OR= 2.3, p< 0.01), the 
drug being a biological agent (OR= 3.9, p< 0.01), administered on a long-term basis 
(OR= 1.8, p< 0.05), indicated for a patient population < 1 in 1,000 (OR= 2.1, p< 0.05), or 
for malignant disease (OR= 5.1, p< 0.01). It was not associated with an indication for 
more severe disease (OR= 2.0, p= 0.06), an MA issued for a new indication (OR= 1.4, 
p= 0.50), or whether a drug was first-of-kind (OR= 1.8, p= 0.10). ConClusions: We 
identified several characteristics associated with the decision to undertake an 
appraisal relating to both the drug and intended patient population that do not 
completely match published topic selection criteria (e.g. severity). Further analyses 
are required to determine which are the most relevant factors in this decision.
PHP201
deTerMinaTion of cosT-effecTiveness THresHold for Malaysia
Lim Y.W., Shafie A.A., Chua G.N., Hassali M.A.A.
Universiti Sains Malaysia, Penang, Malaysia
objeCtives: Decision on the cost-effectiveness (CE) of health care technologies 
usually creates an argument especially when alternatives are more expensive but 
more effective. In this situation, external criterion in the form of CE threshold or 
willingness-to-pay for a quality-adjusted life-year (WTP/QALY) needs to be applied 
to decide on its CE. Nevertheless, the lack of empirical and well-accepted CE thresh-
old in Malaysia is recognized as one of the most important barriers in using health 
technology assessment for decision making. This study was mainly done to deter-
mine the CE threshold value across Malaysian population, estimated in terms of 
societal WTP for a QALY. Methods: A cross-sectional, contingent valuation study 
was conducted using stratified multistage cluster random sampling technique in the 
states of Penang, Kedah, Selangor and Kuala Lumpur Federal Territory. Respondents 
were asked for the socioeconomic background, quality of life and their WTP for a 
hypothetical EQ-5D health state scenario (treatment, extended life in terminal ill-
ness and life saving situations with three health severities – mild, moderate and 
severe, and two QALY gained levels – 0.2 QALY and 0.4 QALY) using pre-designed 
questionnaires. Interval model analysis was applied to determine the CE thresh-
old. Results: One thousand thirteen respondents aged between 20–60 years old 
who can understand either English or Malay language were interviewed face-to-
face. The mean value of CE threshold was determined at the range of MYR 19,929 to 
MYR 28,469 (~ USD 6,200 to USD 8,900). ConClusions: By comparing our results to 
Malaysian GDP per capita in the year 2013; ~ MYR 33,754 (~ USD 10,548), we noted 
that the mean WTP/QALY is ranged between 0.59–0.84 times of GDP per capita.
PHP202
sysTeMaTic review of econoMic evaluaTion of HealTH TecHnologies 
develoPed in Brazil froM 1980-2013
Decimoni T.C.1, Leandro R.1, Soarez P.1, Craig D.2
1Sao Paulo University, São Paulo, Brazil, 2University of York, York, Brazil
objeCtives: The aim of this study is to review published economic evaluation of 
health technologies conducted in Brazil. Methods: Systematic review of economic 
evaluations studies published in MEDLINE, EMBASE, LILACS, SciELO, NHS EED, HTA 
Database, Web of Science, SCOPUS, BVS ECOS and SISREBRATS from 1980 to 2013. 
Full (Cost consequence analysis - CCA, cost minimization analysis - CMA, cost-
effectiveness analysis - CEA, cost-utility analysis - CUA, and cost-benefit analysis 
- CBA) and partial (cost description - CD and cost analysis - CA) economic evalua-
tion studies were eligible for inclusion if at least one of the authors was Brazilian 
and was affiliated to a Brazilian institution. Two independent reviewers screened 
articles for relevance and carried out data extraction. Disagreements were resolved 
through discussion or through consultation with a third reviewer. We performed a 
qualitative narrative synthesis. Results: We identified 11946 records and 557 met 
inclusion criteria. One hundred and ninety (34.1%) were full (of these, 56.6% CEA, 
20.3% CCA, 12.7% CUA, 5.6% CMA, and 4.7% CBA), and 367 were partial economic 
evaluation (of these, 64.7% CD and 32.3% CA). The main health problem studied were 
Infectious and Parasitic diseases (17.1%), Diseases of the Circulatory System (12.3%) 
and Neoplams (10.3%). The majority (72.9%) was conducted by authors from the 
southeast region, and south region (12.6%), mainly linked to academia (69.5%), and 
54.2% were published in medical and 18.9% in public health journals. Seventy-two 
(14.7%) studies reported to be funded by industry and 16% was considered to have 
conﬂict of interest. ConClusions: There was a considerable growth in the conduct 
and publication of economic evaluation studies in Brazil. A qualitative evaluation 
of the methodology used in those studies is important to legitimize their use in the 
process of local decision-making.
PHP203
a liTeraTure review of PaTienT advocacy grouP (Pag) involveMenT 
in HTa
Hicks N.1, Hawken N.A.2, Arvin-berod C.1, Toumi M.3
1Commutateur, Paris, France, 2Creativ-Ceutical, Luxembourg, Luxembourg, 3University Aix-
Marseille, Marseille, France
objeCtives: Patient input is an important part of the assessment process, yet some-
times seen as having a low evidence base. Previous work by the authors shows more 
research is needed on identifying how the patient group contribution is impacting 
decision making. Our objective was to review and critically appraise existing pub-
lications on PAG involvement in HTA. Methods: A search in Pubmed, Cochrane 
and ISPOR databases since 2009 was undertaken to identify studies on patients 
or PAG involvement in the HTA decision. Studies were evaluated for relevancy. 
We extracted information on perceptions of patient input, process improvement 
recommendations, comparison of patient pathways and specific type of patient 
input desired. Two reviewers extracted methodological details, study designs, and 
outcomes into summary tables. Results: We identified 21 articles out of a total of 
18,829 studies. Articles covered multiple subject areas. Process improvements were 
most common (4 studies) followed by current perceptions (3 studies), comparison 
of patient pathways (2 studies) and specific type of patient input desired (1 study). 
Research methodologies and stakeholders varied widely including telephone, web 
audit, interview /questionnaire and literature review. Stakeholders varied between 
national & international HTA agencies, experts and patient groups. Three studies 
involved patient groups and one involved patients. These studies informed the role, 
process and nature of input but did not address the impact on HTA decision mak-
ing. ConClusions: Compared to other HTA areas there is a lack of published mate-
rial on PAG involvement. There have been many attempts to provide a framework 
for patient involvement but so far none has been used in HTA decision-making. 
Existing data does not help to quantify role of the patient in HTA decision making. 
Additional research is needed to understand and quantify patient group input in 
HTA decisions.
PHP204
Trends and key decision drivers for rejecTing an orPHan drug 
suBMission across five differenT HTa agencies
Mardiguian S., Stefanidou M., Sheppard F.
PAREXEL, London, UK
objeCtives: Access to orphan drugs is often inconsistent, and is hindered by dif-
ficulties in demonstrating value in HTA appraisals due to the small patient popula-
tions and insufficient data. To inform future submissions, we examined the trends 
and key decision drivers that resulted in a submission being rejected across five HTA 
agencies. Methods:  The Orphanet database was searched for orphan drugs with a 
marketing authorisation between 2002 and 2014. To assume a certain level of com-
petition, awareness and commercial potential, rare diseases for which two or more 
orphan drugs were available were selected. Decisions from five HTA agencies were 
considered: AWMSG (Wales), CADTH (Canada), NICE (England), PBAC (Australia), 
and SMC (Scotland). Assessments that resulted in a rejection were examined for 
key decision drivers, and for trends and variation by disease type. Results: A total 
of 28 licensed orphan drugs were available for the treatment of eight rare diseases. 
The number of orphan drugs assessed, and rejection rates, varied by HTA agency; 
PBAC and SMC had the lowest rejection rates (4/18; 22% and 6/22; 27%, respectively), 
while NICE had the highest rejection rate with 40% (4/10). Uncertainties regarding 
clinical efficacy, and concerns over the robustness of economic evidence were the 
key decision drivers that led to a rejection. Examination of data by disease type 
indicated a trend towards higher rejection rates for diseases with a higher preva-
lence rate. ConClusions: The proportion of rejected submissions varied by HTA 
agency, particularly within the HTA bodies in the UK, highlighting inconsistencies 
in decision-making. An association between prevalence rate and the proportion of 
rejected submissions was found, with lower rates of disease prevalence correlating 
with higher acceptance rates. This is most likely due to the lower budget impact 
incurred in smaller patient populations.
PHP205
PredicTors of gerMan aMnog decisions and gkv reBaTe 
negoTiaTions: a daTaBase analysis
Verleger K.1, Schoeman O.1, Schmidt R.1, Wilke T.2, Heeg B.1
1Pharmerit International, Berlin, Germany, 2IPAM - Institute for Pharmacoeconomics and 
Medication Logistics, Wismar, Germany
objeCtives: G-BA, IQWiG and GKV are the main governmental stakeholders in 
the German AMNOG process. Based on manufacturer-submitted dossiers, the G-BA 
assesses the drugs’ additional benefit per pre-defined subgroup. Subsequently, the 
GKV negotiates rebates by drug. This research aims to describe factors influenc-
ing GB-A decisions and assess the association between additional benefit and 
rebate. Methods: All G-BA decisions up to March 2014 were analyzed. Univariate 
logistic regression was used to investigate the relationship of G-BA decisions 
(dependent variable: additional benefit (y/n) per subgroup) with study character-
istics. Study characteristics included were disease area (ATC-code), superiority/
non-inferiority study design, comparators used in the submitted trials (in/direct; 
in/adequate comparator according to GBA [“ZVT”]), main area of claimed benefit 
e.g. overall survival (OS). Linear regression was used to assess the impact of added 
benefit (in at least one subgroup) on rebate. Results: Sixty-eight G-BA decisions, 
with in total 137 G-BA subgroups, were included and analyzed. In total, 60.3% of 
assessments resulted in an additional benefit. Most commonly, dossiers were sub-
mitted to the G-BA for ATC-codes L and A (39.7%; 19.1%). Out of 40 ATC-code L sub-
groups (27 drugs), 70.0% resulted in a positive assessment, with 50% demonstrating 
a benefit in OS. Univariate logistic regression showed a significant relationship 
between added benefit and: ATC-codes A/J/L; improvements in morbidity; adverse 
events; direct comparators; and the ZVT (ORs: 0.1; 11.2; 6.0; 55.2; 24.3; 20.9; 15.2; all 
p< 0.05). All drugs showing an OS advantage received a positive benefit assessment. 
Added benefit reduced the rebate significantly by 13.1% (p< 0.05). ConClusions: 
Key factors for a positive G-BA benefit assessment are improved OS, morbidity, and 
adverse events, demonstrated through the use of direct “ZVT” comparators. ATC-
codes J and L carry the highest chance of gaining a positive assessment. The rebate 
negotiated with the GKV decreases significantly if an added benefit is determined.
PHP206
nice resTricTiveness coMPared To THe MarkeT auTHorizaTion
Jaksa A, Westbrook L., Rubinstein E., Daniel K., Ho Y.S.
Context Matters, Inc., New York, NY, USA
objeCtives: To determine how often NICE recommendations are more restrictive 
than the market authorizations. Methods: 161 NICE Technology Appraisal deci-
sions from 2007-2013 were evaluated. These reviews included 80 unique drugs from 
37 disease conditions. For each generic drug included in a review, the corresponding 
